Joseph Petrosino

Department Chair

Baylor College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Aims/hypothesis The nPOD-Virus group collaboratively applied innovative technologies to detect and sequence viral RNA in pancreas and other tissues from organ donors with type 1 diabetes. These analyses involved the largest number of pancreas samples collected to date. The aim of the current work was to examine the presence of enterovirus RNA in pancreas and lymphoid tissues of organ donors with and without type 1 diabetes. Methods We analysed pancreas, spleen, pancreatic lymph nodes and duodenum samples from the following groups: (1) donors with type 1 diabetes ( n =71) with ( n =35) or without ( n =36) insulin-containing islets; (2) donors with single or double islet autoantibody positivity without diabetes ( n =22); and (3) autoantibody-negative donors without diabetes (control donors) ( n =74). Five research laboratories participated in this collaborative effort using approaches for unbiased discovery of RNA viruses (two RNA-Seq platforms), targeted detection of Enterovirus A–D species using RT-PCR, and tests for virus growth in cell culture. Results Direct RNA-Seq did not detect virus signal in pancreas samples, whereas RT-PCR detected enterovirus RNA confirmed by sequencing in low amounts in pancreas samples in three of the five donor groups: donors with type 1 diabetes with insulin-containing islets, 16% (5/32) being positive; donors with single islet autoantibody positivity, 53% (8/15) being positive; and non-diabetic donors, 8% (4/49) being positive. Detection of enterovirus RNA was significantly more frequent in single islet autoantibody-positive donors compared with donors with type 1 diabetes with insulin-deficient islets ( p <0.001) and control (non-diabetic) donors ( p =0.004). In some donors, pancreatic lymph nodes were also positive. RT-PCR detected enterovirus RNA also in the spleen of a small number of donors and virus enrichment in susceptible cell lines before RT-PCR resulted in much higher rate in spleen positivity, particularly in donors with type 1 diabetes. Interestingly, the enterovirus strains detected did not cause a typical lytic infection, possibly reflecting their persistence-prone nature. Conclusions/interpretation This was the largest coordinated effort to examine the presence of enterovirus RNA in the pancreas of organ donors with type 1 diabetes, using a multitude of assays. These findings are consistent with the notion that donors with type 1 diabetes and donors with islet autoantibodies may carry a low-grade enterovirus infection in the pancreas and lymphoid tissues. Graphical Abstract

Year:

2025

Aims/hypothesis Previous pathology studies have associated enterovirus infections with type 1 diabetes by examining the enterovirus capsid protein 1 (VP1) in autopsy pancreases obtained near diabetes diagnosis. The Network for Pancreatic Organ Donors with Diabetes (nPOD) has since obtained pancreases from organ donors with type 1 diabetes (with broad age and disease duration) and donors with disease-associated autoantibodies (AAbs), the latter representing preclinical disease. Two accompanying manuscripts from the nPOD-Virus Group report primary data from a coordinated analysis of multiple enterovirus indices. We aimed to comprehensively assess the association of multiple enterovirus markers with type 1 diabetes. Methods The nPOD-Virus Group examined pancreases from 197 donors, recovered between 2007 and 2019, classified into five groups: donors with type 1 diabetes, with residual insulin-containing islets (T1D-ICI group, n =41) or with only insulin-deficient islets (T1D-IDI, n =42); donors without diabetes who are AAb-negative (ND, n =83); and rare donors without diabetes expressing a single AAb (AAb + , n =22) or multiple AAbs (AAb ++ , n =9). We assessed the overall association of multiple indicators of enterovirus infection, case-by-case and between donor groups, as well as assay agreement and reproducibility, using various statistical methods. We examined data from 645 assays performed across 197 nPOD donors. Results Detection of enterovirus indices by independent laboratories had high reproducibility, using both enterovirus-targeted and unbiased methods. T1D-ICI donors had significantly higher ( p <0.001) proportions of positive assay outcomes (58.4%) vs T1D-IDI (10.3%), ND (17.8%) and AAb-positive donors (AAb + 24.6%; AAb ++ 35.0%). Head-to-head comparisons revealed increased proportions of donors positive in two independent assays among T1D-ICI vs ND donors (VP1/HLA class I [HLA-I], p <0.0001; VP1/enterovirus-specific RT-PCR (EV-PCR), p =0.076; EV-PCR/HLA-I, p =0.016; proteomics/HLA-I, p <0.0001; VP1/proteomics, p =0.06). Among 110 donors examined for three markers (VP1, EV-PCR and HLA-I), 83.3% of T1D-ICI donors were positive in two or more assays vs 0% of ND ( p <0.001), 26.7% of AAb + ( p =0.006), 28.6% of AAb ++ ( p =0.023) and 0% of T1D-IDI ( p <0.001) donors. Conclusions/interpretation The nPOD-Virus Group conducted, to date, the largest and most comprehensive analysis of multiple indices of pancreatic enterovirus infections in type 1 diabetes; these were more prevalent in T1D-ICI and AAb ++ donors than in other groups. Their preferential detection of these indices in donors with residual beta cells and autoimmunity implicates enterovirus infections across disease progression stages and supports a contribution to beta cell loss, directly or indirectly, even after diagnosis. The relatively small number of infected cells and the low amount of viral RNA support the existence of non-acute, low level, possibly persistent enterovirus infections in the pancreas. Graphical Abstract

Year:

2025

Year:

2025

Viruses are abundant across all Earth’s environments and infect all classes of cellular life. Despite this, viruses are something of a black box for genomics scientists. Their genetic diversity is greater than all other lifeforms combined, their genomes are often overlooked in sequencing datasets, they encode polyproteins, and no function can be inferred for a large majority of their encoded proteins. For these reasons, scientists need robust, performant, well-documented, extensible tools that can be deployed to conduct sensitive and specific analyses of sequencing data to discover virus genomes - even those with high divergence from known references - and annotate their genes. Here, we present Cenote-Taker 3. This command line interface tool processes genome assemblies and/or metagenomic assemblies with modules for virus discovery, prophage extraction, and annotation of genes and other genetic features. Benchmarks show that Cenote-Taker 3 outperforms most tools for virus gene annotation in both speed (wall time) and accuracy. For virus discovery benchmarks, Cenote-Taker 3 performs well compared to geNomad, and these tools produce complementary results. Cenote-Taker 3 is freely available on Bioconda, and its open-source code is maintained on GitHub ( https://github.com/mtisza1/Cenote-Taker3 ).

Year:

2025

Year:

2024

Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely coupled with tobacco-associated lung adenocarcinoma in a human-relevant mouse model. Furthermore, we demonstrated that the loss of the antimicrobial protein Lcn2 in these mice exacerbates protumor inflammatory phenotypes while further reducing microbial diversity. Yet, how gut microbiome alterations impinge on lung adenocarcinoma development remains poorly understood. In this study, we investigated the role of gut microbiome changes in lung adenocarcinoma development using fecal microbiota transfer and delineated a pathway by which gut microbiome alterations incurred by loss of Lcn2 fostered the proliferation of proinflammatory bacteria of the genus Alistipes , triggering gut inflammation. This inflammation propagated systemically, exerting immunosuppression within the tumor microenvironment, augmenting tumor growth through an IL6-dependent mechanism and dampening response to immunotherapy. Corroborating our preclinical findings, we found that patients with lung adenocarcinoma with a higher relative abundance of Alistipes species in the gut showed diminished response to neoadjuvant immunotherapy. These insights reveal the role of microbiome-induced inflammation in lung adenocarcinoma and present new potential targets for interception and therapy.

Year:

2024

Collaborators (21)

John Kaddis

Beckman Research Institute

UNITED STATES
View details

Sarah Richardson

Professor of Cellular Biomedicine

University of Exeter

UNITED KINGDOM
View details

matthew ross

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Cheuk Hong Leung

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kristi Hoffman

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Julius O Nyalwidhe

Professor and Director, Center for Biomedical Proteomics

Eastern Virginia Medical School

UNITED STATES
View details

Jyotirmaya Behera

Assistant Professor

Indian Institute of Technology, Delhi

View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel Depledge

Associate Professor

University College London

UNITED KINGDOM
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

sami oikarinen

University of Tampere

FINLAND
View details

Robert Jenq

Professor

City Of Hope National Medical Center

UNITED STATES
View details

Seyed Javad Moghaddam

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Arvind Varsani

Associate Professor

Arizona State University

UNITED STATES
View details

Michael Tisza

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kathrin Maedler

Director; Islet Biology Laboratory

University of Bremen

GERMANY
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details